Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations

被引:48
作者
Wilson, KM
Johnson, EIM
Croom, HA
Richards, KM
Doughty, L
Cunningham, PH
Kemp, BE
Branson, BM
Dax, EM
机构
[1] St Vincents Inst, Natl Serol Reference Lab, Melbourne, Vic, Australia
[2] St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia
[3] Natl Ctr HIV STD & TB Prevent, Ctr Dis Control & Prevent, Atlanta, GA USA
关键词
HIV diagnostic tests; acute infection; antibodies; epidemiology; seroprevalence; surveillance;
D O I
10.1097/00002030-200411190-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To identify a specific marker of recent HIV-1 infection. Design: The humoral immune response in individuals recently infected with HIV-1 was followed by analysing the antibody isotype-specific response generated to HIV-1 antigens in sequential samples collected during and following seroconversion. Methods: Antibody isotype-specific HIV-1 Western blots were analysed to identify interactions indicative of recent HIV-1 infection. These responses were further quantified using an antibody isotype-specific enzyme-linked immunoabsorbent assay based on recombinant HIV-1 antigens. Results: During maturation of the immune response to HIV-1 infection, a rapid and enduring IgG(1) isotype response was seen to all the major proteins transcribed by env, gag and pol. An early transient peak of IgG(3) reactivity to p24 was observed over an interval of approximately 1-4 months following HIV-1 infection. The presence of IgG(3) reactivity to p24 permitted established infection to be distinguished from recently infected individuals during this time period. Conclusion: An assay for anti-p24 IgG(3) reactivity would provide an estimate of the incidence of HIV infection that may be applicable for epidemiological surveys as well as for monitoring new infections during vaccine trials and for managing treatment programmes. (C) 2004 Lippincott Willianis Wilkins.
引用
收藏
页码:2253 / 2259
页数:7
相关论文
共 17 条
[1]   An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1 [J].
Binley, JM ;
Arshad, H ;
Fouts, TR ;
Moore, JP .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (12) :1007-1015
[2]  
BROLIDEN PA, 1989, CLIN EXP IMMUNOL, V76, P216
[3]   TIME-COURSE OF DETECTION OF VIRAL AND SEROLOGIC MARKERS PRECEDING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SEROCONVERSION - IMPLICATIONS FOR SCREENING OF BLOOD AND TISSUE DONORS [J].
BUSCH, MP ;
LEE, LLL ;
SATTEN, GA ;
HENRARD, DR ;
FARZADEGAN, H ;
NELSON, KE ;
READ, S ;
DODD, RY ;
PETERSEN, LR .
TRANSFUSION, 1995, 35 (02) :91-97
[4]   THE ABSENCE OR LOSS OF ANTIBODIES OF HIGH-AFFINITY TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) IS ASSOCIATED WITH DISEASE PROGRESSION IN HIV-1-INFECTED PATIENTS [J].
CHARGELEGUE, D ;
STANLEY, CM ;
OTOOLE, CM ;
COLVIN, BT ;
STEWARD, MW .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (03) :897-898
[5]   A LONGITUDINAL-STUDY OF THE IGG ANTIBODY-RESPONSE TO HIV-1 P17 GAG PROTEIN IN HIV-1+ PATIENTS WITH HEMOPHILIA - TITER AND AVIDITY [J].
CHARGELEGUE, D ;
OTOOLE, CM ;
COLVIN, BT .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1993, 93 (03) :331-336
[6]   Reactivity of sera from systemic lupus erythematosus and Sjogren's syndrome patients with peptides derived from human immunodeficiency virus p24 capsid antigen [J].
Deas, JE ;
Liu, LG ;
Thompson, JJ ;
Sander, DM ;
Soble, SS ;
Garry, RF ;
Gallaher, WR .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1998, 5 (02) :181-185
[7]   MULTIFACTORIAL NATURE OF HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE - IMPLICATIONS FOR THERAPY [J].
FAUCI, AS .
SCIENCE, 1993, 262 (5136) :1011-1018
[8]  
GENESCA J, 1989, LANCET, V2, P1023
[9]  
Gouws E, 2002, J ACQ IMMUN DEF SYND, V29, P531, DOI 10.1097/00126334-200204150-00015
[10]   New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes [J].
Janssen, RS ;
Satten, GA ;
Stramer, SL ;
Rawal, BD ;
O'Brien, TR ;
Weiblen, BJ ;
Hecht, FM ;
Jack, N ;
Cleghorn, FR ;
Kahn, JO ;
Chesney, MA ;
Busch, MP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :42-48